- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07911137
Effect of Oxybutynin on Opioid Use After Urologic Surgery in Children
A Randomized Double-Blind Placebo-Controlled Trial Evaluating the Opioid-Sparing Effect of Preoperative Oxybutynin in Children Undergoing Urologic Reconstruction
The goal of this clinical trial is to determine whether giving oxybutynin before urologic reconstruction surgery reduces the amount of opioid pain medication needed in children. Oxybutynin is a medication that helps reduce bladder spasms, which can cause pain and discomfort after surgery.
The main question this study aims to answer is:
Does giving oxybutynin before surgery reduce the amount of opioid pain medication children need during the first 6 hours after surgery?
Researchers will compare oxybutynin with a placebo (a tablet containing no active medication) to see whether oxybutynin reduces opioid use after surgery.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Background
Children undergoing pediatric urologic reconstruction, such as pyeloplasty and hypospadias repair, frequently require urinary drainage via ureteral stent and/or urethral catheter. These tools cause the bladder to contract involuntarily, mediated by muscarinic receptors (i.e., bladder spasms). This leads to increased catheter-related bladder discomfort (CRBD), bladder spasm-associated pain and postoperative opioid use.
Oxybutynin, an antimuscarinic agent, reduces the occurrence of bladder spasms and thus the number and severity of CRBD events and bladder spasm-related pain. This reduction in discomfort/pain may contribute to decreased postoperative opioid use, as suggested by retrospective pediatric data.
Postoperative management of urologic reconstruction surgeries includes PRN administration of opioids and oxybutynin to treat bladder spasm-related discomfort/pain according to institutional practice and prior pediatric urology literature. Oxybutynin takes 1 hour to reach its maximal plasma concentration, during which time significant bladder spasm-related symptoms may already be present when the child is awake. However, opioids such as morphine achieve their maximal effects within 10 minutes. Because opioids are much faster-acting than oxybutynin, this may increase the likelihood of concomitant administration when the child is awake with discomfort/pain. We are therefore considering using oxybutynin preoperatively, rather than just postoperatively PRN, since its plasma concentration will already be maximal or near-maximal upon waking, which may lead to less CRBD, bladder spasm-related pain, and postoperative opioid use.
This study aims to reduce the use of opioids to treat pediatric patients undergoing urologic reconstruction. Opioids carry significant side effects that include nausea, vomiting, respiratory depression, addiction, urinary retention, tolerance, and constipation. Combined with the ongoing opioid epidemic, there is an increased effort among caregivers, including nurses and physicians, to find other means to reduce pain in pediatric patients.
Opioid therapy has also been shown not to be effective in treating bladder spasm-related symptoms (e.g., CRBD, bladder spasm-related pain). As opposed to opioids, oxybutynin directly targets bladder spasm-associated symptoms, and may reduce the severity of side effects. Side effects of oxybutynin include dry mouth, constipation, dizziness, urinary retention, and blurry vision.
Emerging pediatric urology data suggest that a single preoperative dose may reduce early postoperative opioid requirements. However, current evidence is retrospective and non-randomized. There is no high-quality randomized pediatric study evaluating the opioid sparing effects of preoperative oxybutynin administration in pediatric patients undergoing urologic reconstruction.
Study Need, Importance, and Hypothesis
Urologic reconstruction surgeries requiring a stent and/or catheter can be associated with significant CRBD, bladder-spasm associated pain and morbidity. With the growing recognition of the need to decrease opioid medication, our primary objective is to assess whether the administration of preoperative oxybutynin reduces opioid use. We hypothesize that preoperative oxybutynin reduces early postoperative opioid use in children undergoing pyeloplasty or hypospadias repair.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 4
Kontakty a umístění
Studijní kontakt
- Jméno: Hayder Al-Kazzaz
- Telefonní číslo: 403-955-7757
- E-mail: hayder.alkazzaz@ucalgary.ca
Studijní záloha kontaktů
- Jméno: Bryce Weber, MD
- Telefonní číslo: 403-955-2776
- E-mail: bryce.weber@albertahealthservices.ca
Studijní místa
-
-
Alberta
-
Calgary, Alberta, Kanada, T2B6A8
- Alberta Children's Hospital
-
Vrchní vyšetřovatel:
- Bryce Weber
-
Kontakt:
- Hayder Al-Kazzaz
- Telefonní číslo: 403-955-7757
- E-mail: hayder.alkazzaz@ucalgary.ca
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- All children aged 0 to 17 years old admitted for pyeloplasty or hypospadias repair. There is no minimum weight for inclusion
Exclusion Criteria:
- Contraindications to anticholinergic medications
- Urinary retention disorders
- Gastrointestinal obstruction/ileus
- Contraindications to anesthetic protocol, including 1) allergy to any anesthetic medication in protocol, 2) refusal of regional technique, 3) contraindications to ketorolac (i.e., recent GI bleed, recent intracranial bleed, renal dysfunction, acute kidney injury)
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Preoperative Oxybutynin
Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
|
Komparátor placeba: Preoperative Placebo
Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Total Cumulative Postoperative Opioid Consumption (MME/kg)
Časové okno: From the end of surgery through 6 hours postoperatively
|
Total cumulative morphine milligram equivalents per kilogram (MME/kg) administered within 6 hours after surgery |
From the end of surgery through 6 hours postoperatively
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Proportion of Participants Receiving Postoperative Opioids
Časové okno: From the end of surgery through 6 hours postoperatively
|
Whether any opioid medication was administered within 6 hours after surgery (yes/no) |
From the end of surgery through 6 hours postoperatively
|
|
Postoperative Pain Scores (NRS/FLACC)
Časové okno: At 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours following postoperative removal of the laryngeal mask airway or endotracheal tube
|
Pain assessed using age-appropriate validated scales: the Numeric Rating Scale (NRS; 0-10) or the Face, Legs, Activity, Cry, Consolability (FLACC; 0-10) scale. Higher scores indicate greater pain. |
At 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours following postoperative removal of the laryngeal mask airway or endotracheal tube
|
|
Proportion of Participants Receiving Postoperative Rescue Oxybutynin
Časové okno: From the end of surgery through 6 hours postoperatively
|
Whether oxybutynin was administered as needed (PRN) within 6 hours after surgery (yes/no). |
From the end of surgery through 6 hours postoperatively
|
|
Total Cumulative Postoperative Oxybutynin Consumption (mg/kg)
Časové okno: From the end of surgery through 6 hours postoperatively
|
Total cumulative dose of oxybutynin administered per kilogram of body weight during the first 6 hours after surgery. |
From the end of surgery through 6 hours postoperatively
|
|
Incidence of Adverse Events
Časové okno: From preoperative study medication administration through postoperative discharge
|
Occurrence of adverse events, including dry mouth, flushing, tachycardia, agitation, sedation, and urinary retention. |
From preoperative study medication administration through postoperative discharge
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění genitálií
- Bolest
- Neurologické projevy
- Pooperační komplikace
- Patologické procesy
- Onemocnění pohlavních orgánů, muž
- Mužská urogenitální onemocnění
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Vrozené vady
- Urogenitální abnormality
- Nemoci penisu
- Vrozené, dědičné a neonatální nemoci a abnormality
- Patologické stavy, příznaky a symptomy
- Příznaky a symptomy
- Bolest, pooperační
- Hypospadias
- Multicystická dysplazie ledvin, bilaterální
- Oxybutynin
Další identifikační čísla studie
- REB26-1464
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .